An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
RenovoRx to Present at the H.C. Wainwright Bioconnect Virtual Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
RenovoRx, a biopharmaceutical company focused on targeted cancer therapies, will have CEO Shaun Bagai participate in the H.C. Wainwright Bioconnect Virtual Conference from January 10-13, 2022. An on-demand investor presentation will be available starting January 10 at 7:00 am EST. Management will also hold 1-on-1 meetings during the conference. RenovoRx is known for its RenovoTAMP therapy platform, which uses localized treatment for difficult tumors, and is currently studying its lead product, RenovoGem, in a Phase 3 trial for pancreatic cancer.
Positive
None.
Negative
None.
LOS ALTOS, Calif.--(BUSINESS WIRE)--
RenovoRx, Inc. (NASDAQ: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced that Shaun Bagai, Chief Executive Officer, will participate in the H.C. Wainwright Bioconnect Virtual Conference on behalf of RenovoRx. The conference will be held January 10-13, 2022.
Mr. Bagai’s investor presentation will be available on-demand beginning January 10th at 7:00 am EST.
Management will be available during the H.C. Wainwright Bioconnect conference for 1-on-1 meetings with the investment community. To schedule a meeting please reach out to your H.C. Wainwright representative or KCSA Strategic Communications by emailing RenovoRx@kcsa.com.
For further information about the H.C. Wainwright Bioconnect conference and to register to attend virtually click here.
RenovoRx is a clinical-stage biopharmaceutical company focused on fighting cancer through the localized treatment of difficult to treat tumors via its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMPTM) therapy platform. RenovoTAMP utilizes approved chemotherapeutics with validated mechanisms of action and well-established safety and side effect profiles, with the goal of increasing their efficacy, improving their safety, and widening their therapeutic window. RenovoRx’s lead product candidate, RenovoGemTM, is a combination of gemcitabine and our patented delivery system, RenovoCath®, and is regulated by the FDA as a novel oncology drug product to treat unresectable locally advanced pancreatic cancer (LAPC). RenovoGem is currently being studied in the Phase 3 TIGeR-PaC trial for the treatment of LAPC.
RenovoRx’s patent portfolio includes seven U.S. patents for its technology. RenovoRx has been granted Orphan Drug Designation for intra-arterial delivery of gemcitabine for the treatment of both pancreatic cancer and bile duct cancer.
RenovoRx won the Drug Delivery Technology category of the Fierce Innovation Awards – Life Sciences Edition 2020 for its RenovoTAMP technology.
H.C. Wainwright is a full‐service investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. H.C. Wainwright & Co. also provides research and sales and trading services to institutional investors. According to Sagient Research Systems, H.C. Wainwright’s team is ranked as the #1 Placement Agent in terms of aggregate CMPO (confidentially marketed public offering), RD (registered direct offering) and PIPE (private investment in public equity) executed cumulatively since 1998.
For more information visit H.C. Wainwright & Co. on the web at www.hcwco.com
RenovoRx, Inc. Shaun R. Bagai, CEO
Christopher J. Lehman, CFO
Investor Contact:
KCSA Strategic Communications Valter Pinto or Jack Perkins T:212-896-1254
RenovoRx@kcsa.com
Source: RenovoRx, Inc.
FAQ
What event will RenovoRx, Inc. participate in?
RenovoRx will participate in the H.C. Wainwright Bioconnect Virtual Conference from January 10-13, 2022.
When will the investor presentation by RenovoRx's CEO be available?
The on-demand investor presentation by CEO Shaun Bagai will be available starting January 10, 2022, at 7:00 am EST.
How can I schedule a meeting with RenovoRx during the conference?
To schedule a meeting with RenovoRx management during the H.C. Wainwright Bioconnect conference, contact your H.C. Wainwright representative or email KCSA Strategic Communications.
What is RenovoRx's lead product candidate?
RenovoRx's lead product candidate is RenovoGem, which is being studied in the Phase 3 TIGeR-PaC trial for the treatment of unresectable locally advanced pancreatic cancer.
What is the focus of RenovoRx's research and development?
RenovoRx focuses on localized treatment of difficult-to-treat tumors using its proprietary RenovoTAMP therapy platform.
